SYGNIS Pharma AG – Product Pipeline Review – H2 2011

Date: December 1, 2011
Pages: 47
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S03ABCDCD11EN
Leaflet:

Download PDF Leaflet

SYGNIS Pharma AG - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “SYGNIS Pharma AG - Product Pipeline Review - H2 2011” provides data on the SYGNIS Pharma AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, SYGNIS Pharma AG’s corporate website, SEC filings, investor presentations and featured press releases, both from SYGNIS Pharma AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • SYGNIS Pharma AG - Brief SYGNIS Pharma AG overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of SYGNIS Pharma AG human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of SYGNIS Pharma AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the SYGNIS Pharma AG’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate SYGNIS Pharma AG’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of SYGNIS Pharma AG in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the SYGNIS Pharma AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with SYGNIS Pharma AG.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of SYGNIS Pharma AG and identify potential opportunities in those areas.
SYGNIS Pharma AG Snapshot
SYGNIS Pharma AG Overview
Key Information
Key Facts
SYGNIS Pharma AG – Research and Development Overview
Key Therapeutic Areas
SYGNIS Pharma AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
SYGNIS Pharma AG – Pipeline Products Glance
SYGNIS Pharma AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
SYGNIS Pharma AG – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
SYGNIS Pharma AG – Drug Profiles
AX200
AX201
KIBRA Modulators
SY300
SYGNIS Pharma AG – Pipeline Analysis
SYGNIS Pharma AG – Pipeline Products by Therapeutic Class
SYGNIS Pharma AG - Pipeline Products By Target
SYGNIS Pharma AG – Pipeline Products by Route of Administration
SYGNIS Pharma AG – Pipeline Products by Molecule Type
SYGNIS Pharma AG – Recent Pipeline Updates
SYGNIS Pharma AG - Dormant Projects
SYGNIS Pharma AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Company's Recent Developments
SYGNIS Pharma AG, Recent Developments
Dec 22, 2010: SYGNIS Announces Data Safety Monitoring Board Recommendation For Phase II Study Of AX200
Mar 22, 2011: SYGNIS Enters Final Stage With Phase II Efficacy Study Of AX200 For Treatment Of Acute Stroke
Sep 15, 2011: SYGNIS Further Strengthens Patent Position For AX200 For Treatment Of Stroke
Aug 09, 2011: SYGNIS Successfully Completes Patient Recruitment For AXIS 2 Study
Nov 03, 2011: SYGNIS Completes Treatment In AXIS 2 Efficacy Study
Financial Deals Landscape
SYGNIS Pharma AG, Deals Summary
SYGNIS Pharma AG, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Amnestix Secures Seed Financing
Partnerships
LION Bioscience Enters Into An Agreement With Xennex
LION bioscience Enters Into An Agreement With TEMIS
Licensing Agreements
SYGNIS Pharma Enters Into Licensing Agreement For European Patent
Equity Offering
SYGNIS Pharma Completes Rights Issue Of Common Stock For $0.21 Million
SYGNIS Pharma Announces Private Placement Of $49.21 Million
SYGNIS Pharma Completes Private Placement Of $25 Million
Acquisition
SYGNIS Pharma Acquires Amnestix
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

SYGNIS Pharma AG, Key Information
SYGNIS Pharma AG, Key Facts
SYGNIS Pharma AG – Pipeline by Therapy Area and Indication, H2 2011
SYGNIS Pharma AG – Pipeline by Stage of Development, H2 2011
SYGNIS Pharma AG – Monotherapy Products in Pipeline, H2 2011
SYGNIS Pharma AG - Phase II, H2 2011
SYGNIS Pharma AG - Phase I, H2 2011
SYGNIS Pharma AG – Pre-Clinical, H2 2011
SYGNIS Pharma AG - Pipeline By Therapeutic Class, H2 2011
SYGNIS Pharma AG - Pipeline By Target, H2 2011
SYGNIS Pharma AG – Pipeline By Route of Administration, H2 2011
SYGNIS Pharma AG – Pipeline By Molecule Type, H2 2011
SYGNIS Pharma AG – Recent Pipeline Updates, H2 2011
SYGNIS Pharma AG - Dormant Developmental Projects, 2010
SYGNIS Pharma AG, Subsidiaries
SYGNIS Pharma AG, Deals Summary
Amnestix Secures Seed Financing
LION Bioscience Enters Into An Agreement With Xennex
LION bioscience Enters Into An Agreement With TEMIS
SYGNIS Pharma Enters Into Licensing Agreement For European Patent
SYGNIS Pharma Completes Rights Issue Of Common Stock For $0.21 Million
SYGNIS Pharma Announces Private Placement Of $49.21 Million
SYGNIS Pharma Completes Private Placement Of $25 Million
SYGNIS Pharma Acquires Amnestix

LIST OF FIGURES

SYGNIS Pharma AG – Pipeline by Therapy Area and Indication, H2 2011
SYGNIS Pharma AG – Pipeline by Stage of Development, H2 2011
SYGNIS Pharma AG – Monotherapy Products in Pipeline, H2 2011
SYGNIS Pharma AG – Pipeline By Therapeutic Class, H2 2011
SYGNIS Pharma AG – Pipeline By Molecule Type, H2 2011

Ask Your Question

SYGNIS Pharma AG – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: